Valaciclovir
Is It Right for You?
A complete guide to Valaciclovir — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Valaciclovir?
Valaciclovir (spelled valacyclovir in North American usage) is an orally administered antiviral medication belonging to the nucleoside analogue class. It is the L-valyl ester prodrug of aciclovir — meaning it is pharmacologically inactive as administered but is rapidly converted to aciclovir following absorption, primarily by intestinal and hepatic esterase enzymes. This prodrug design is clinically significant: it enables oral valaciclovir to achieve plasma aciclovir concentrations that are three to five times higher than an equivalent dose of oral aciclovir, greatly improving bioavailability and allowing less frequent dosing.
Valaciclovir is active against herpesviruses, including Herpes simplex virus types 1 and 2 (HSV-1, HSV-2), Varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and Cytomegalovirus (CMV). Its primary clinical indications in primary care include the treatment and suppression of oral herpes (cold sores), genital herpes, and herpes zoster (shingles), as well as prophylaxis in immunocompromised patients.
Valaciclovir is available generically and also under the brand name Valtrex. It is supplied as 500 mg film-coated tablets, with treatment regimens using varying doses and frequencies depending on the indication.
What Conditions Does Valaciclovir Treat?
Valaciclovir is prescribed for:
Cold sores are caused by Herpes simplex virus type 1 (HSV-1), though HSV-2 can occasionally cause orolabial infection. The virus persists lifelong in the trigeminal ganglion following primary infection and reactivates in response to triggers such as sun exposure, illness, fever, stress, hormonal changes, or immunosuppression. Valaciclovir taken at the onset of prodromal symptoms (tingling, burning, itching) or at the appearance of a cold sore significantly reduces healing time, lesion duration, and viral shedding. A single-day high-dose regimen (2 g twice in one day, 12 hours apart) is approved for episodic treatment and has been shown to abort cold sore development in some patients when started during the prodrome phase.
Genital herpes is most commonly caused by HSV-2, though HSV-1 is now responsible for a growing proportion of genital cases, particularly in younger adults. Valaciclovir is used in two distinct ways in genital herpes management:
Episodic treatment: Taken during an outbreak to reduce the severity and duration of symptoms (pain, ulceration, itching), accelerate lesion healing, and reduce the period of viral shedding. Treatment is most effective when started as early as possible — ideally within 24 to 72 hours of symptom onset. First episodes of genital herpes, which are typically more severe and prolonged than recurrences, are treated with a longer course.
Suppressive therapy: Taken daily on a continuous basis to reduce the frequency and severity of recurrences, reduce subclinical viral shedding (which can transmit infection even without visible lesions), and decrease the risk of transmission to uninfected sexual partners. Suppressive therapy is particularly recommended for patients with frequent recurrences (typically defined as six or more per year), those in serodiscordant relationships (one partner HSV-positive, one HSV-negative), and those experiencing significant psychological distress related to recurrent outbreaks.
Shingles occurs when the varicella-zoster virus, which lies dormant in dorsal root ganglia following primary chickenpox infection, reactivates — typically during periods of reduced cellular immunity associated with advancing age, immunosuppression, or illness. Valaciclovir initiated within 72 hours of shingles rash onset (or while new lesions are still forming) significantly reduces the severity and duration of the acute rash, pain, and viral replication. Critically, early antiviral treatment also reduces the risk and severity of post-herpetic neuralgia (PHN) — the persistent, often debilitating neuropathic pain that can persist for months or years after the acute rash resolves and represents the most serious complication of shingles in older adults.
In these serious infections, intravenous aciclovir is the standard of care in the acute setting. Valaciclovir may be used for oral step-down therapy in selected patients following initial IV treatment.
Valaciclovir is used at high doses for CMV prophylaxis following solid organ transplantation, particularly renal transplantation. This is a specialist indication managed within transplant medicine.
Valaciclovir is indicated for
How Does Valaciclovir Work?
After oral administration, valaciclovir is absorbed from the gastrointestinal tract and hydrolysed almost completely to aciclovir. Aciclovir then enters virally infected cells, where it is selectively phosphorylated to aciclovir monophosphate by the viral thymidine kinase enzyme. This step is critical to aciclovir's selectivity — the viral thymidine kinase phosphorylates aciclovir far more efficiently than human cellular kinases, meaning the drug accumulates preferentially in infected cells. Cellular kinases then convert aciclovir monophosphate to aciclovir triphosphate, the pharmacologically active form.
Aciclovir triphosphate competitively inhibits viral DNA polymerase and acts as a chain terminator: when incorporated into the growing viral DNA strand, it lacks the 3'-hydroxyl group required for chain elongation, permanently halting viral DNA replication. The preferential activation in infected cells and the high selectivity of viral DNA polymerase for aciclovir triphosphate mean that human cells are largely spared, accounting for aciclovir's excellent tolerability and wide therapeutic index.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Valaciclovir tablets may be taken with or without food. Adequate hydration is recommended, particularly at higher doses, to reduce the risk of crystalluria and renal complications.
Side Effects of Valaciclovir
Valaciclovir is generally well tolerated, but some side effects may occur.
- Headache: Reported in a significant proportion of patients across clinical trials; usually mild and self-limiting.
- Nausea: Particularly at higher doses (e.g. 2 g for cold sores, 1 g three times daily for shingles). Taking tablets with food reduces nausea.
- Dizziness
- Vomiting
- Diarrhoea or abdominal pain
- Kidney problems — reduced urine output, swelling, or increased creatinine
- Neurological effects — confusion, agitation, hallucinations, seizures
- Severe allergic reaction — swelling of face, lips, or throat, difficulty breathing
- Blood disorders (rare) — unusual bruising or bleeding, especially in immunocompromised patients
Valaciclovir is generally well tolerated, but in rare cases it can cause serious adverse effects, particularly in older adults, those with kidney impairment, or at high doses. It may affect the kidneys or nervous system, leading to symptoms such as confusion, agitation, hallucinations, or reduced urine output. Adequate hydration is important to reduce renal risk. In very rare cases, severe conditions such as thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome (especially in immunocompromised patients) may occur. Immediate medical attention is required if neurological symptoms, unusual bruising, or decreased urine output develop.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Valaciclovir
Important Warnings
Dose reduction is mandatory in patients with reduced kidney function. Failure to adjust the dose is the most common cause of valaciclovir-related neurological toxicity. Always inform your clinician of any known kidney problems.
Adequate fluid intake is important, particularly at higher doses (shingles treatment, CMV prophylaxis). Poor hydration increases the risk of aciclovir crystallising in the kidneys.
Valaciclovir is most effective when started early in the course of infection. For shingles, treatment must begin within 72 hours of rash onset. For cold sores, starting during the prodromal phase (tingling, burning) produces the best outcomes. For genital herpes recurrences, patients with a history of frequent episodes are often given a prescription to self-start at the first sign of an outbreak.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Valaciclovir FAQs
Aciclovir is the active antiviral agent. Valaciclovir is a prodrug — an inactive precursor that the body converts into aciclovir after absorption. The key advantage is that this conversion produces aciclovir blood levels three to five times higher than an equivalent oral aciclovir dose, meaning valaciclovir can be taken less frequently while achieving better antiviral activity. For example, shingles requires aciclovir five times daily for 7 days, whereas valaciclovir only needs to be taken three times daily for the same duration.
No. Valaciclovir controls herpes infections but does not eradicate them. Herpes simplex and varicella-zoster viruses establish lifelong latency in nerve ganglia that cannot currently be cleared by available antivirals. Valaciclovir suppresses viral replication during treatment and reduces the frequency and severity of reactivations, but the virus remains dormant in the body and may reactivate in future, especially during periods of illness, stress, or immunosuppression.
When started at the very first sign of a cold sore (tingling, burning before the blister appears), the single-day 2 g twice-daily regimen can abort or significantly truncate the episode in many patients. For established cold sores (where the blister has already formed), valaciclovir typically reduces healing time by 1 to 2 days and reduces pain.
Yes. Continuous suppressive therapy with valaciclovir 500 mg once daily is safe and effective for long-term use. It is typically reviewed after 12 months to reassess whether suppression remains necessary, as recurrence frequency tends to decline over time for many patients with HSV-2. Long-term suppression is well tolerated; valaciclovir does not cause significant organ toxicity with prolonged use at suppressive doses in patients with normal renal function.
Daily suppressive therapy significantly reduces, but does not eliminate, the risk of transmission. Studies show that valaciclovir 500 mg daily reduces the risk of genital herpes transmission to an uninfected partner by approximately 48% in heterosexual serodiscordant couples. Combined with consistent condom use, risk reduction is greater. It is important to continue using barrier contraception and to have an open conversation with sexual partners about herpes status.
Extensive pregnancy registry data on aciclovir (the active metabolite of valaciclovir) have not demonstrated an increased risk of birth defects or miscarriage. Valaciclovir is generally used when clinically indicated during pregnancy, particularly for the treatment of primary genital herpes, severe recurrent herpes, or shingles, where the risks of untreated infection may outweigh any theoretical risks of treatment. The decision should always be made in consultation with a clinician.
Yes. The shingles treatment regimen requires 1 g taken three times daily for 7 consecutive days. It is important not to miss doses, and treatment should ideally be started within 72 hours of rash onset to achieve the greatest reduction in acute disease severity and the best protection against post-herpetic neuralgia.